BOSTON--(BUSINESS WIRE)--Ora, Inc., the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today that Paul Colvin has been appointed Chief Operating Officer (COO). An experienced CRO leader, Paul will report directly to Chairman & CEO, Stuart Abelson.
“Paul is a world-class operating executive with a proven track-record of managing large complex businesses. His patient focused, service-minded approach directly aligns with Ora’s mission to serve ophthalmology innovators around the world,” said Stuart Abelson, Chairman & CEO, Ora Inc. “In his role as COO, Paul will lead Ora’s continued global growth and market leadership through focus on scaling Ora’s people, processes and technologies with the operational excellence, high quality, scientific rigor and white-glove customer service for which Ora is known.”
With over 30 years of experience building and leading global teams in both pharmaceuticals and pharma services, Paul began his career as a pharmacist and then spent 14 years with Eli Lilly in increasing roles of responsibility in the US, Europe, and Asia. Recruited by PPD, he spent 12 years leading their clinical development business. In 2018 he joined Syneos Health as President of clinical development solutions and was later promoted to Chief Business Officer in 2021.
“Ora’s deep therapeutic knowledge, relationships in the ophthalmology ecosystem, understanding of the patient’s journey, standardized scales, disease models, regulatory experience and unique patient enrollment techniques allow Ora to deliver outstanding value to clients and the patients they serve,” said Paul Colvin, COO. “Ora’s focus on culture and people has created a stable and talented team with an unmatched track-record for helping clients achieve success.”
About Ora, Inc.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 82 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn
Ora® and Ora Logo are registered trademarks of Ora, Inc.
